debrisoquin has been researched along with bufuralol in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (51.61) | 18.7374 |
| 1990's | 7 (22.58) | 18.2507 |
| 2000's | 6 (19.35) | 29.6817 |
| 2010's | 2 (6.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kronbach, T | 1 |
| Bargetzi, MJ; Follath, F; Haefeli, WE; Meyer, UA | 1 |
| Aoyama, T; Gonzalez, FJ; Matsunaga, E; Meyer, UA; Zanger, UM; Zeugin, T | 1 |
| Alvarez, F; Gueguen, M; Jacqz-Aigrain, E; Robieux, I; Zanger, UM | 1 |
| Gonzalez, FJ; Hardwick, JP; Inaba, T; Kalow, W; Tyndale, RF | 1 |
| Balant, L; Dayer, P; Kupfer, A; Leemann, T; Striberni, R | 1 |
| Smith, RL | 1 |
| Dayer, P; Kronbach, T; Küpfer, A; Leemann, T; Meyer, UA | 1 |
| McManus, ME | 1 |
| Hardwick, JP; Meyer, UA; Vilbois, F; Zanger, UM | 1 |
| Catin, T; Gut, J; Kronbach, T; Mathys, D; Meyer, UA | 1 |
| Dayer, P; Eichelbaum, M; Kronbach, T; Meyer, UA | 1 |
| Catin, T; Dayer, P; Gut, J; Kronbach, T; Meyer, UA; Zanger, U | 1 |
| Boobis, AR; Davies, DS; Hampden, CE; Murray, S | 1 |
| Davis, GG; Distlerath, LM; Guengerich, FP; Martin, MV; Reilly, PE; Wilkinson, GR | 1 |
| Balant, L; Balant-Gorgia, A; Courvoisier, F; Dayer, P; Fabre, J; Kupfer, A | 1 |
| Catin, T; Dayer, P; Gasser, R; Gut, J; Kronbach, T; Meyer, UA | 1 |
| Meier, PJ; Meyer, UA; Minder, C; Minder, EI; Müller, HK | 1 |
| Boobis, AR; Davies, DS; McManus, ME; Minchin, RF; Murray, S; Schwartz, DM; Thorgeirsson, SS | 1 |
| Dayer, P; Fabre, J; Pometta, D; Suenram, A | 1 |
| Crespi, CL; Gelboin, HV; Gonzalez, FJ; Penman, BW; Reece, J; Smith, T; Yang, CS | 1 |
| Chow, T; Funae, Y; Hiroi, T; Imaoka, S; Wan, J; Yabusaki, Y | 1 |
| Crespi, C; Gaedigk, A; Leeder, JS; Marcucci, KA; Pearce, RE; Steimel, DT | 1 |
| Chow, T; Funae, Y; Hiroi, T; Imaoka, S | 1 |
| Friis, C; Skaanild, MT | 1 |
| Adedoyin, A; Bebia, Z; Branch, RA; Burckart, GJ; Carcillo, JA; Frye, RF; Knoll, C; Romkes, M; Roskos, L; Sereika, S; Thummel, K; Venkataramanan, R; Wilson, JW | 1 |
| Funae, Y; Hanioka, N; Hichiya, H; Imoto, K; Isobe, T; Kiryu, K; Naito, S; Narimatsu, S; Yamamoto, S | 1 |
| Guo, B; He, MM; Li, C; Liu, H; Shen, H; Wang, L; Wrighton, SA | 1 |
| Funk, C; Haddad, S; Poulin, P | 1 |
| Henderson, CJ; McLaughlin, LA; Scheer, N; Stanley, LA; Wolf, CR | 1 |
1 trial(s) available for debrisoquin and bufuralol
| Article | Year |
|---|---|
Coordinated intrahepatic and extrahepatic regulation of cytochrome p4502D6 in healthy subjects and in patients after liver transplantation.
Topics: Actins; Adrenergic Agents; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cytochrome P-450 CYP2D6; Debrisoquin; Electrophoresis, Polyacrylamide Gel; Ethanolamines; Female; Gene Expression Regulation, Enzymologic; Genotype; Humans; Hydroxylation; In Vitro Techniques; Liver; Liver Transplantation; Male; Microsomes, Liver; Middle Aged; Monocytes; Phenotype; Reference Values; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2003 |
30 other study(ies) available for debrisoquin and bufuralol
| Article | Year |
|---|---|
Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6.
Topics: Adrenergic beta-Antagonists; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Dextromethorphan; Ethanolamines; Humans; Microsomes, Liver; Mixed Function Oxygenases; Spectrometry, Fluorescence; Substrate Specificity | 1991 |
Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo.
Topics: Adult; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Debrisoquin; Dextromethorphan; Ethanolamines; Flecainide; Humans; In Vitro Techniques; Kinetics; Male; Microsomes, Liver; Mixed Function Oxygenases; Phenotype; Sparteine | 1990 |
Sequence requirements for cytochrome P-450IID1 catalytic activity. A single amino acid change (Ile380 Phe) specifically decreases Vmax of the enzyme for bufuralol but not debrisoquine hydroxylation.
Topics: Adrenergic beta-Antagonists; Animals; Cell Line; Chimera; Cloning, Molecular; Cytochrome P-450 Enzyme System; Debrisoquin; DNA, Neoplasm; Ethanolamines; Hydroxylation; Isoleucine; Kinetics; NADP; Rats; Recombination, Genetic; Spectrophotometry; Substrate Specificity; Vaccinia virus | 1990 |
Cytochrome P450IID subfamily in non-human primates. Catalytical and immunological characterization.
Topics: Animals; Autoantibodies; Binding, Competitive; Cross Reactions; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Debrisoquin; Dextromethorphan; Ethanolamines; Humans; Isoenzymes; Kinetics; Macaca fascicularis; Microsomes, Liver; Mixed Function Oxygenases; Oxidoreductases, O-Demethylating | 1991 |
Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry.
Topics: Animals; Blotting, Western; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; Immunochemistry; In Vitro Techniques; Kinetics; Liver; Quinidine; Rats; Rats, Inbred Strains; Sparteine | 1990 |
Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.
Topics: Adrenergic beta-Antagonists; Adult; Debrisoquin; Ethanolamines; Humans; Kinetics; Liver; Oxidation-Reduction; Polymorphism, Genetic; Sparteine | 1985 |
Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance.
Topics: Adrenergic beta-Antagonists; Animals; Biological Availability; Blood Pressure; Debrisoquin; Ethanolamines; Glucuronates; Humans; Hydroxylation; Kinetics; Lipids; Metoprolol; Phenotype; Polymorphism, Genetic; Propranolol; Solubility; Structure-Activity Relationship; Timolol | 1985 |
Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
Topics: Adrenergic beta-Antagonists; Adult; Chromatography, High Pressure Liquid; Debrisoquin; Ethanolamines; Gas Chromatography-Mass Spectrometry; Humans; Hydroxylation; Isoquinolines; Kinetics; Male; Microsomes, Liver; Oxidation-Reduction; Phenotype; Polymorphism, Genetic; Sparteine; Stereoisomerism | 1986 |
Metabolic characterization of human liver microsomal cytochromes P-450 involved in the oxidation of debrisoquine, bufuralol and the carcinogen 2-acetylaminofluorene.
Topics: 2-Acetylaminofluorene; Adrenergic beta-Antagonists; Aldrin; Carcinogens; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; In Vitro Techniques; Isoquinolines; Microsomes, Liver; Oxidation-Reduction | 1987 |
Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.
Topics: Benzene Derivatives; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; Hydroxylation; Immunologic Techniques; Immunosorbent Techniques; Isoenzymes; Isoquinolines; Kinetics; Microsomes, Liver; NADP; Polymorphism, Genetic; Stereoisomerism; Substrate Specificity | 1988 |
High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Dextromethorphan; Ethanolamines; Humans; Isoenzymes; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Oxidoreductases; Oxidoreductases, O-Demethylating; Polymorphism, Genetic | 1987 |
Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Topics: Adult; Aged; Binding, Competitive; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; Hydroxylation; Isoenzymes; Isoquinolines; Kinetics; Microsomes, Liver; Middle Aged; Phenotype; Polymorphism, Genetic; Quinidine; Sparteine | 1987 |
Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
Topics: Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; Hydroxylation; Isoenzymes; Isoquinolines; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Sparteine; Structure-Activity Relationship | 1986 |
Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.
Topics: Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; Hydroxylation; In Vitro Techniques; Kinetics; Liver; Mixed Function Oxygenases; Polymorphism, Genetic; Stereoisomerism | 1985 |
Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.
Topics: Amino Acids; Animals; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; Hydroxylation; Immunoelectrophoresis; Kinetics; Liver; Male; Mixed Function Oxygenases; Oxidation-Reduction; Oxidoreductases; Phenacetin; Polymorphism, Genetic; Rats; Rats, Inbred Strains; Stereoisomerism | 1985 |
Oxidation phenotype and beta-blockers.
Topics: Adrenergic beta-Antagonists; Debrisoquin; Ethanolamines; Humans; Metoprolol; Oxidation-Reduction; Phenotype | 1983 |
[Pharmacokinetic and clinical consequences of the genetic polymorphism of oxidation].
Topics: Adrenergic beta-Antagonists; Adult; Alleles; Chromatography, High Pressure Liquid; Debrisoquin; Ethanolamines; Humans; Hydroxylation; Oxidation-Reduction; Polymorphism, Genetic | 1983 |
Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.
Topics: Adrenergic beta-Antagonists; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; Hydroxylation; Isoenzymes; Isoquinolines; Kinetics; Microsomes, Liver; Molecular Weight; Oxidation-Reduction; Polymorphism, Genetic; Substrate Specificity | 1984 |
Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation.
Topics: Adrenergic beta-Antagonists; Debrisoquin; Ethanolamines; Humans; Hydroxylation; In Vitro Techniques; Inactivation, Metabolic; Isoquinolines; Kinetics; Microsomes, Liver; Phenotype; Polymorphism, Genetic | 1984 |
Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
Topics: 2-Acetylaminofluorene; Aldrin; Biotransformation; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; Hydroxylation; Isoquinolines; Microsomes, Liver; Oxidation-Reduction | 1984 |
Apparent lack of influence of the genetic drug oxidation status on plasma cholesterol concentration in man.
Topics: Adult; Cholesterol; Cholesterol, HDL; Debrisoquin; Ethanolamines; Female; Humans; Male; Oxidation-Reduction; Pharmaceutical Preparations; Phenotype; Triglycerides | 1984 |
Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6.
Topics: B-Lymphocytes; Cell Fractionation; Cell Line; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; DNA; Ethanolamines; Gene Expression; Humans; Kinetics; Mixed Function Oxygenases; Mutagens; Nitrosamines; Substrate Specificity | 1993 |
Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity.
Topics: Animals; Cloning, Molecular; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Gene Expression; Humans; Hydroxylation; Immunoblotting; Isoenzymes; Lidocaine; Liver; Microsomes; Plasmids; Rats; Recombinant Proteins; Saccharomyces cerevisiae; Sequence Homology, Nucleic Acid; Spectrophotometry; Substrate Specificity | 1997 |
Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.
Topics: Animals; Cells, Cultured; Chlorocebus aethiops; COS Cells; Cytochrome P-450 CYP2D6; Debrisoquin; Dextromethorphan; Ethanolamines; Genetic Variation; Insecta; Kinetics; Phenotype; Substrate Specificity; Transfection | 2002 |
Catalytic specificity of CYP2D isoforms in rat and human.
Topics: Alcohol Oxidoreductases; Animals; Aryl Hydrocarbon Hydroxylases; Catalysis; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Debrisoquin; Ethanolamines; Humans; In Vitro Techniques; Isoenzymes; Magnetic Resonance Spectroscopy; Microsomes, Liver; Mixed Function Oxygenases; Propranolol; Rats; Recombinant Proteins; Substrate Specificity | 2002 |
Is cytochrome P450 CYP2D activity present in pig liver?
Topics: Animals; Antibodies, Monoclonal; Cytochrome P-450 CYP2D6; Debrisoquin; Dextromethorphan; Ethanolamines; Female; Male; Microsomes, Liver; Substrate Specificity; Swine; Swine, Miniature | 2002 |
The roles of amino acid residues at positions 43 and 45 in microsomal contents and enzymatic functions of rat CYP2D1 and CYP2D2.
Topics: Alcohol Oxidoreductases; Amino Acid Sequence; Amino Acids; Animals; Aryl Hydrocarbon Hydroxylases; Blotting, Western; Carbon Monoxide; Cytochrome P450 Family 2; Debrisoquin; DNA Primers; DNA, Complementary; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Ethanolamines; Glycine; Kinetics; Leucine; Liver; Microsomes; Microsomes, Liver; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Oxygen; Proline; Rats; Recombinant Proteins; Sequence Homology, Amino Acid; Spectrophotometry; Valine | 2004 |
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
Topics: Atomoxetine Hydrochloride; Cocaine; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Dextromethorphan; Enzyme Inhibitors; Ethanolamines; Fluoxetine; Humans; Hydroxylation; Imipramine; Kinetics; Microsomes; Molecular Structure; Nortriptyline; Polymorphism, Single Nucleotide; Propylamines; Quinidine; Recombinant Proteins; Thioridazine; Tramadol | 2007 |
Extrapolating in vitro metabolic interactions to isolated perfused liver: predictions of metabolic interactions between R-bufuralol, bunitrolol, and debrisoquine.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Debrisoquin; Drug Interactions; Ethanolamines; In Vitro Techniques; Liver; Propanolamines; Rats | 2010 |
Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
Topics: Animals; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochromes b5; Debrisoquin; Ethanolamines; Female; Humans; Male; Mice, Knockout; Microsomes, Liver; Nifedipine; Sex Factors; Triazolam | 2015 |